Trade-Ideas LLC identified Arrowhead Research ( ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Arrowhead Research as such a stock due to the following factors:

  • ARWR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $31.0 million.
  • ARWR has traded 146,884 shares today.
  • ARWR is up 4.1% today.
  • ARWR was down 13.2% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ARWR with the Ticky from Trade-Ideas. See the FREE profile for ARWR NOW at Trade-Ideas

More details on ARWR:

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. ARWR has a PE ratio of 18. Currently there are 2 analysts that rate Arrowhead Research a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Arrowhead Research has been 1.5 million shares per day over the past 30 days. Arrowhead Research has a market cap of $427.8 million and is part of the health care sector and drugs industry. The stock has a beta of 2.21 and a short float of 26.7% with 3.09 days to cover. Shares are down 1.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Arrowhead Research as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 37.0% when compared to the same quarter one year ago, falling from -$11.63 million to -$15.94 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ARROWHEAD RESEARCH CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to -$13.12 million or 34.17% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Looking at the price performance of ARWR's shares over the past 12 months, there is not much good news to report: the stock is down 54.18%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • ARROWHEAD RESEARCH CORP's earnings per share declined by 22.7% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ARROWHEAD RESEARCH CORP continued to lose money by earning -$1.23 versus -$1.32 in the prior year. For the next year, the market is expecting a contraction of 22.8% in earnings (-$1.51 versus -$1.23).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.